UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 300

Sortiert nach

Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)

Bone marrow transplantation (Basingstoke), 2013-02, Vol.48 (2), p.186-190

2013

Volltextzugriff (PDF)

Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3

Mini reviews in medicinal chemistry, 2011-06, Vol.11 (6), p.528

2011

Volltextzugriff (PDF)

Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab

Mini reviews in medicinal chemistry, 2011-06, Vol.11 (6), p.536

2011

Volltextzugriff (PDF)

Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients

Leukemia, 2005-02, Vol.19 (2), p.217-222

2005

Volltextzugriff (PDF)

Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups

Haematologica (Roma), 2012-08, Vol.97 (8), p.1142-1148

2012

Volltextzugriff (PDF)

Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Haematologica (Roma), 2014-10, Vol.99 (10), p.1574

2014

Volltextzugriff (PDF)

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis

Bone marrow transplantation (Basingstoke), 2018-01, Vol.53 (1), p.105-107

2018

Volltextzugriff (PDF)

Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Haematologica (Roma), 2010-06, Vol.95 (6), p.983-988

2010

Volltextzugriff (PDF)

T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy

Clinical and experimental immunology, 2003-09, Vol.133 (3), p.461-466

2003

Volltextzugriff (PDF)

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S17

2023

Volltextzugriff (PDF)

Expression of the 67-kDa Laminin Receptor in Acute Myeloid Leukemia Cells Mediates Adhesion to Laminin and Is Frequently Associated with Monocytic Differentiation

Clinical cancer research, 1999-06, Vol.5 (6), p.1465-1472

1999

Volltextzugriff (PDF)

Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant

Bone marrow transplantation (Basingstoke), 1999-05, Vol.23 (10), p.1029-1037

1999

Volltextzugriff (PDF)

Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned

Haematologica (Roma), 2016-03, Vol.101 (3), p.319

2016

Volltextzugriff (PDF)

Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses

The Journal of immunology (1950), 2004-02, Vol.172 (3), p.1960-1969

2004

Volltextzugriff (PDF)

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2024-03, Vol.390 (11), p.994

2024

Volltextzugriff (PDF)

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Haematologica (Roma), 2014-02, Vol.99 (2), p.262

2014

Volltextzugriff (PDF)

Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab) : Treatment and Hematopoietic Stem Cell Transplantation in Aplastic Anemia

Bone marrow transplantation (Basingstoke), 2013, Vol.48 (2), p.186-190

2013

Volltextzugriff (PDF)

Paroxysmal nocturnal hemoglobinuria and eculizumab

Haematologica (Roma), 2010-04, Vol.95 (4), p.523-526

2010

Volltextzugriff (PDF)

Use of eltrombopag in aplastic anemia in Europe

Annals of hematology, 2019-06, Vol.98 (6), p.1341-1350

2019

Volltextzugriff (PDF)

In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR β-CDR3 sequencing

The Lancet (British edition), 2004-07, Vol.364 (9431), p.355-364

2004

Volltextzugriff (PDF)

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

Blood, 2005-08, Vol.106 (3), p.841-851

2005

Volltextzugriff (PDF)

Immunological derangement in hypocellular myelodysplastic syndromes

Translational medicine @ UniSa, 2014-01, Vol.8, p.31-42

2014

Volltextzugriff (PDF)

Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell–receptor restriction in large granular lymphocyte leukemia

Blood, 2005-10, Vol.106 (8), p.2769-2780

2005

Volltextzugriff (PDF)

Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria

British journal of haematology, 2004-06, Vol.125 (6), p.804-813

2004

Volltextzugriff (PDF)

Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by Vβ CDR3 spectratyping and flow cytometry

Blood, 2002-07, Vol.100 (1), p.178-183

2002

Volltextzugriff (PDF)

1 – 25 von 300

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(274)
Mit Volltextzugriff
(268)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(167)
Life Sciences & Biomedicine
(150)
Humans
(134)
Hematology
(96)
Male
(54)
Female
(52)
Adult
(50)
Middle Aged
(43)
Biological And Medical Sciences
(39)
Hemoglobinuria, Paroxysmal - Drug Therapy
(38)
Medical Sciences
(38)
Immunology
(33)
Adolescent
(30)
Hematologic And Hematopoietic Diseases
(30)
Paroxysmal Nocturnal Hemoglobinuria
(28)
Aged
(26)
Anemia
(21)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(21)
Oncology
(21)
Bone Marrow
(20)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab)

Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3

Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab

Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients

Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups

Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis

Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy

OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

Expression of the 67-kDa Laminin Receptor in Acute Myeloid Leukemia Cells Mediates Adhesion to Laminin and Is Frequently Associated with Monocytic Differentiation

Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant

Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned

Molecular Analysis of TCR Clonotypes in LGL: A Clonal Model for Polyclonal Responses

Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab) : Treatment and Hematopoietic Stem Cell Transplantation in Aplastic Anemia

Paroxysmal nocturnal hemoglobinuria and eculizumab

Use of eltrombopag in aplastic anemia in Europe

In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR β-CDR3 sequencing

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

Immunological derangement in hypocellular myelodysplastic syndromes

Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell–receptor restriction in large granular lymphocyte leukemia

Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria

Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by Vβ CDR3 spectratyping and flow cytometry

Suchergebnisse filtern